Brushing Off Clinical Setback, Cerulean Pharma Inc. Tees Up $75 Million IPO
3/11/2014 7:26:51 AM
Cerulean Pharma whiffed on its first attempt to prove that a nanoparticle-based cancer drug its been developing could help terminally ill lung cancer patients live longer. Now the Cambridge, MA-based company is going public to get the financial backing to see if the drug has better luck treating other cancer types. Cerulean aims to raise as much as $75 million through an IPO and list on the Nasdaq under the ticker symbol “CERU.” Leerink Partners, Canaccord Genuity, JMP Securities, and Wedbush Securities are underwriting the offering.
Help employers find you! Check out all the jobs and post your resume.
comments powered by